Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14002243 | 0.88 | MAOB (0.59) | MEN1KMT2AMAOBGCKSMN1; SMN2 | |
| SCHEMBL391547 | 0.87 | MEN1 (0.71) | LMNAHPGDMEN1KMT2AMRGPRX4 | |
| SCHEMBL1592632 | 0.84 | MEN1 (0.47) | HPGDMEN1KMT2AMRGPRX4MAOB | |
| SCHEMBL183994 | 0.84 | LMNA (0.70) | LMNAHPGDMEN1KMT2AMRGPRX4 | |
| SCHEMBL4391166 | 0.84 | NOTUM (0.45) | LMNARAB9APDK2 | |
| SCHEMBL3811208 | 0.84 | MAOB (0.44) | LMNAHPGDMEN1KMT2AMRGPRX4 | |
| SCHEMBL8235722 | 0.84 | CYP4F2 (0.47) | LMNAHPGDMEN1KMT2AMRGPRX4 | |
| SCHEMBL731011 | 0.83 | KAT6A (0.41) | LMNAMEN1KMT2AMRGPRX4NPC1 | |
| SCHEMBL29788280 | 0.83 | LMNA (0.65) | LMNAHPGDMEN1KMT2AMRGPRX4 | |
| SCHEMBL340311 | 0.83 | LMNA (0.65) | LMNAHPGDMEN1KMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| CN-101014595-A | Novel cyclic aminobenzoic acid derivative | KYORIN SEIYAKU KK (JP) | 2007-08-08 | — | — | CN | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
| CN-1080257-C | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-03-06 | — | — | CN | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| CN-1123545-A | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | CN | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | LMNA 3338/4885HPGD 1767/4885MEN1 2932/4885 |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | LMNA 3764/4885HPGD 2115/4885MEN1 3209/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | LMNA 3764/4885HPGD 2115/4885MEN1 3209/4885 |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | LMNA 1906/4885HPGD 2412/4885MEN1 3887/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | LMNA 3697/4885HPGD 1997/4885MEN1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.